1. Oct 2026
Description
(AWP Alliance News) - Sandoz published a pre-close brief ahead of its nine-month and third-quarter 2026 sales update, due on Oct. 28, 2026. Full-year 2026 guidance stayed unchanged, with net sales expected to rise at constant currencies by a mid-to-high single-digit percentage, with core EBITDA margin seen expanding by about 100 basis points. The company reiterated it expects no material contribution from any potential generic semaglutide launch in 2026, with overall pricing forecast to fall by a mid-single-digit percentage.
It flagged a potential 2-percentage-point currency tailwind to full-year net sales if mid-July spot rates persist, with no material effect on the core EBITDA margin. A results call is set for Oct. 28, 2026.
https://docs.publicnow.com/3852955C16535687B1437359967295B2E8788963
Disclaimer: This news brief was created using generative artificial intelligence. Sandoz Group AG published the original content used to generate this news brief on October 01, 2026, and is solely responsible for the information contained therein.
